Table 3:
Primary endpoint CAC score: changes in volume scores (mm3) between baseline and 12 and 18 months in participants of the VitaVasK study.
| Model 1 | Model 2 | Model 3 | ||
|---|---|---|---|---|
| CAC volume estimates (SE) | ||||
| Vitamin K | Baseline | 1045.6 (347.8) | 1237.0 (400.4) | 1381.2 (400.4) |
| 12 months | 1187.4 (349.9) | 1378.1 (401.7) | 1521.8 (401.7) | |
| 18 months | 1242.2 (351.5) | 1433.1 (404.5) | 1580.0 (403.9) | |
| Control | Baseline | 1388.4 (286.5) | 1422.3 (322.5) | 1517.8 (313.0) |
| 12 months | 1796.0 (287.4) | 1829.8 (323.2) | 1904.2 (313.9) | |
| 18 months | 1997.8 (291.8) | 2032.6 (328.6) | 2109.8 (317.4) | |
| Changes in volume score versus baseline within groups | ||||
| Vitamin K | Baseline versus 12 months | 141.8 (138.3), 0.3092 | 141.1 (141.9), 0.3241 | 140.7 (143.4), 0.3308 |
| Baseline versus 18 months | 196.6 (169.5), 0.2505 | 196.2 (176.8), 0.2716 | 198.8 (178.1), 0.2690 | |
| Control | Baseline versus 12 months | 407.5 (116.4), 0.0009 | 407.5 (117.4), 0.0010 | 386.4 (124.3), 0.0029 |
| Baseline versus 18 months | 609.3 (148.6), 0.0001 | 610.3 (149.9), 0.0001 | 592.0 (154.9), 0.0003 | |
| Changes in volume score versus baseline between groups | ||||
| Vitamin K versus control | Baseline versus 12 months | 265.7 (180.8), 0.1468 | 266.4 (184.2), 0.1534 | 245.7 (189.8), 0.2006 |
| Baseline versus 18 months | 412.7 (225.4), 0.0720 | 414.2 (231.7), 0.0790 | 393.2 (236.0), 0.1012 | |
Data are linear mixed model estimates (SE) and P-value.
Model 1: adjusted for centre; model 2: adjusted for centre, gender and age; model 3: adjusted for centre, gender, age, smoking status and diabetes mellitus. All models automatically adjust for baseline calcification as repeated mixed effects models were used.